Abstracts (HTML) List of Authors

Bahr, AS

Modeling low-grade glioma with cerebral organoids

Baisch, T

Combining Autophagy Inhibition and Temozolomide in Glioblastoma Therapy
Re-assessing the Role of Temozolomide in Glioblastoma Therapy

Bezler, V

Targeting Bcl-2 as Treatment Strategy – Leukaemia versus Glioblastoma

Böhme, L

Enhancement of radiation effects by combined treatment with Decitabine and Abacavir in a murine model of human pediatric medulloblastoma

Buhl, J

Modeling low-grade glioma with cerebral organoids

Capper, D

Modeling low-grade glioma with cerebral organoids

Classen, CF

CDKs as target structures for cancer therapy – an in vitro analysis on patient-derived glioblastoma cell lines

Debatin, K-M

Targeting Bcl-2 as Treatment Strategy – Leukaemia versus Glioblastoma
Combining Autophagy Inhibition and Temozolomide in Glioblastoma Therapy
Re-assessing the Role of Temozolomide in Glioblastoma Therapy

Doerner, E

Giant cell glioblastoma does not represent a distinct entity but stratifies into different genetically defined entities

Fitzel, R

Combining Autophagy Inhibition and Temozolomide in Glioblastoma Therapy
Re-assessing the Role of Temozolomide in Glioblastoma Therapy

Glasow, A

Enhancement of radiation effects by combined treatment with Decitabine and Abacavir in a murine model of human pediatric medulloblastoma

Gringmuth, M

Enhancement of radiation effects by combined treatment with Decitabine and Abacavir in a murine model of human pediatric medulloblastoma

Halatsch, M-E

Targeting Bcl-2 as Treatment Strategy – Leukaemia versus Glioblastoma
Combining Autophagy Inhibition and Temozolomide in Glioblastoma Therapy
Re-assessing the Role of Temozolomide in Glioblastoma Therapy

Herbener, VJ

Combining Autophagy Inhibition and Temozolomide in Glioblastoma Therapy
Re-assessing the Role of Temozolomide in Glioblastoma Therapy

Hernáiz Driever, P

Modeling low-grade glioma with cerebral organoids

Jones, DTW

Model development and implementation of patient-individual ex vivo drug response profiling within the INFORM registry study

Karpel-Massler, G

Targeting Bcl-2 as Treatment Strategy – Leukaemia versus Glioblastoma
Combining Autophagy Inhibition and Temozolomide in Glioblastoma Therapy
Re-assessing the Role of Temozolomide in Glioblastoma Therapy

Kortmann, RD

Enhancement of radiation effects by combined treatment with Decitabine and Abacavir in a murine model of human pediatric medulloblastoma

Kramm, C

Giant cell glioblastoma does not represent a distinct entity but stratifies into different genetically defined entities

Lenaerts, I

Design of ovalbumin-loaded mesoporous silica nanoparticles as proof of concept for the development of personalized anti-cancer nanovaccines

Locquet, J-P

Design of ovalbumin-loaded mesoporous silica nanoparticles as proof of concept for the development of personalized anti-cancer nanovaccines

Makalowski, J

Modulated electrohyperthermia as part of immunogenic cell death treatment in pediatric neuro-oncology

Maletzki, C

CDKs as target structures for cancer therapy – an in vitro analysis on patient-derived glioblastoma cell lines

Milde, T

Model development and implementation of patient-individual ex vivo drug response profiling within the INFORM registry study
Modeling low-grade glioma with cerebral organoids

Mohr, F

Targeting Bcl-2 as Treatment Strategy – Leukaemia versus Glioblastoma

Oehme, I

Model development and implementation of patient-individual ex vivo drug response profiling within the INFORM registry study

Oppermann, S

Model development and implementation of patient-individual ex vivo drug response profiling within the INFORM registry study

Patties, I

Enhancement of radiation effects by combined treatment with Decitabine and Abacavir in a murine model of human pediatric medulloblastoma

Payer, C

Targeting Bcl-2 as Treatment Strategy – Leukaemia versus Glioblastoma

Peterziel, H

Model development and implementation of patient-individual ex vivo drug response profiling within the INFORM registry study

Pfister, S

Model development and implementation of patient-individual ex vivo drug response profiling within the INFORM registry study

Pietsch, T

Giant cell glioblastoma does not represent a distinct entity but stratifies into different genetically defined entities

Rieß, C

CDKs as target structures for cancer therapy – an in vitro analysis on patient-derived glioblastoma cell lines

Schirrmacher, V

Modulated electrohyperthermia as part of immunogenic cell death treatment in pediatric neuro-oncology

Selt, F

Modeling low-grade glioma with cerebral organoids

Seré, S

Design of ovalbumin-loaded mesoporous silica nanoparticles as proof of concept for the development of personalized anti-cancer nanovaccines

Simon, M

Modeling low-grade glioma with cerebral organoids

Stachelscheid, H

Modeling low-grade glioma with cerebral organoids

Strobel, H

Combining Autophagy Inhibition and Temozolomide in Glioblastoma Therapy
Re-assessing the Role of Temozolomide in Glioblastoma Therapy

Stuecker, W

Modulated electrohyperthermia as part of immunogenic cell death treatment in pediatric neuro-oncology

Van Gool, SW

Design of ovalbumin-loaded mesoporous silica nanoparticles as proof of concept for the development of personalized anti-cancer nanovaccines
Modulated electrohyperthermia as part of immunogenic cell death treatment in pediatric neuro-oncology

von Bandemer, H

Targeting Bcl-2 as Treatment Strategy – Leukaemia versus Glioblastoma

Waha, A

Giant cell glioblastoma does not represent a distinct entity but stratifies into different genetically defined entities

Westhoff, M-A

Targeting Bcl-2 as Treatment Strategy – Leukaemia versus Glioblastoma
Combining Autophagy Inhibition and Temozolomide in Glioblastoma Therapy
Re-assessing the Role of Temozolomide in Glioblastoma Therapy

Wiedey, A

Giant cell glioblastoma does not represent a distinct entity but stratifies into different genetically defined entities

Witt, O

Model development and implementation of patient-individual ex vivo drug response profiling within the INFORM registry study
Modeling low-grade glioma with cerebral organoids

Worst, B

Model development and implementation of patient-individual ex vivo drug response profiling within the INFORM registry study

Zimmel, M

Targeting Bcl-2 as Treatment Strategy – Leukaemia versus Glioblastoma

zur Muehlen, A

Giant cell glioblastoma does not represent a distinct entity but stratifies into different genetically defined entities